Related Experiment Videos
Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy
Sydney Tang1, Joseph C K Leung, Loretta Y Y Chan
1Nephrology Division, Department of Medicine, University of Hong Kong and Queen Mary Hospital, Hong Kong, China.
Kidney International
|July 15, 2005
Summary
Mycophenolate mofetil (MMF) significantly reduced proteinuria in IgA nephropathy (IgAN) patients. This treatment also improved serum albumin and IgA levels, suggesting MMF is effective for IgAN.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Primary glomerulopathies are increasingly treated with mycophenolate mofetil (MMF).
- The efficacy of MMF in IgA nephropathy (IgAN) is not well-established.
- IgAN is a common primary glomerulopathy with significant proteinuria.
Purpose of the Study:
- To evaluate the effectiveness of MMF in reducing proteinuria in IgAN patients.
- To assess the impact of MMF on specific pathogenetic factors in IgAN.
- To compare MMF treatment with conventional therapy in IgAN.
Main Methods:
- A randomized controlled trial involving 40 IgAN patients with persistent proteinuria.
- Patients received either MMF or conventional therapy for 24 weeks, with a total follow-up of 72 weeks.
- The primary endpoint was a 50% or greater reduction in proteinuria.
Main Results:
- 80% of patients on MMF achieved the primary endpoint versus 30% on conventional therapy (P=0.0019).
- MMF significantly reduced proteinuria over time, while conventional therapy showed a modest increase.
- MMF treatment led to increased serum albumin, decreased serum IgA, and normalized IgA binding and IL-6 levels.
Conclusions:
- MMF is effective in reducing proteinuria in selected IgAN patients.
- MMF may ameliorate key pathogenetic abnormalities in IgAN.
- MMF offers a potential therapeutic option for IgAN patients with persistent proteinuria.